STAT+: Compass says depression drug has long-lasting benefits

STAT PlusNewsletterThe Readout Compass says depression drug has long-lasting benefits Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenJuly 7, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Plenty of news today, and also a deal that is running out soon: Buy one year of STAT+, get one year free.Advertisement Vertex makes its largest-ever deal Vertex said yesterday it will spend $10 billion to acquire Crinetics Pharmaceuticals, a biotech developing drugs for rare endocrine disorders. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout July 8, 2026 STAT Plus: Europe will accelerate its review of RevMed’s drug Biotech July 8, 2026 STAT Plus: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics Advertisement Biotech July 7, 2026 STAT Plus: FDA approves Vera Therapeutics kidney disease treatment Biotech July 6, 2026 STAT Plus: Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A booms The Readout July 6, 2026 STAT Plus: Four major biotech updates to catch up on Subscriber Picks